Anifrolumab and Dermatomyositis

Published: 4 April 2025| Version 1 | DOI: 10.17632/pydccyf54m.1
Contributors:
Anagha Srivatsa, Wasey Rehman, Rafey Rehman, Meena Moossavi, Steve Daveluy, Geoffrey Potts

Description

The purpose of this systematic review was to evaluate the potential of anifrolumab as a novel treatment for dermatomyositis. We searched the PubMed, Embase, and Cochrane libraries for articles related to anifrolumab and dermatomyositis. Of the 50 articles screened, six met the criteria for inclusion (Figure 1). The 2009 Oxford levels of evidence were used to evaluate the quality of all articles included (Mendeley supplementary table 1).

Files

Institutions

  • Wayne State University School of Medicine

Categories

Dermatology, Dermatomyositis

Licence